title: [Analysis of hemostatic abnormality in various disease using molecular-I. Liver disease].
abstract: We examined the hemostatic abnormality of liver disease using hemostatic molecular markers, i.e. TAT, FPA and SFMC for coagulation, B beta 15-42, FDP, D dimer and PIC for fibrinolysis, t-PA and TM for vessel wall. The molecular markers for coagulation were generally increased in cases of liver disease, which was most sensitively reflected by FPA. On the other hand, it was postulated that SFMC was a marker reflecting the complication of DIC in these cases. Hyperfibrinolysis of liver disease was sensitively reflected by the increase of B beta 15-42, and an occasional increase of SFMC or FDP was thought to indicate the complication of DIC in these cases. A high correlation was found between t-PA and TM. It was postulated that the increase of the both markers in liver disease was due to deteriorated clearance by liver dysfunction, although TM is regarded as a marker reflecting endothelial injury. It was expected that visualization of hemostatic disorder of liver disease was made practical with the use of radar chart of these molecular markers.
authors.affiliation: Central Clinical Laboratory, Teikyo University Hospital, Tokyo.
authors.forename: C
authors.initials: C
authors.lastname: Shimazu
authors.forename: T
authors.initials: T
authors.lastname: Fukuda
authors.forename: N
authors.initials: N
authors.lastname: Yugeta
authors.forename: K
authors.initials: K
authors.lastname: Yasuda
authors.forename: K
authors.initials: K
authors.lastname: Wakasugi
authors.forename: C
authors.initials: C
authors.lastname: Tahara
authors.forename: Y
authors.initials: Y
authors.lastname: Miyajima
authors.forename: M
authors.initials: M
authors.lastname: Kazama
mesh_terms: D000933:Antifibrinolytic Agents / Q000032:analysis; D000990:Antithrombin III / Q000032:analysis; D015415:Biomarkers / Q000097:blood*; D001777:Blood Coagulation; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis; D006487:Hemostasis; D006801:Humans; D008107:Liver Diseases / Q000097:blood*; D010447:Peptide Hydrolases / Q000032:analysis; D010959:Tissue Plasminogen Activator / Q000032:analysis; D000979:alpha-2-Antiplasmin
chemical_list: D000933:Antifibrinolytic Agents; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin